TY - T1的最小抑制浓度较低ns of linezolid against multidrug-resistant tuberculosis strains JF - European Respiratory Journal JO - Eur Respir J SP - 287 LP - 289 DO - 10.1183/09031936.00135014 VL - 45 IS - 1 AU - Sotgiu, Giovanni AU - Centis, Rosella AU - D'Ambrosio, Lia AU - Castiglia, Paolo AU - Migliori, Giovanni Battista Y1 - 2015/01/01 UR - //www.qdcxjkg.com/content/45/1/287.abstract N2 - We thank Weiss T. and colleagues who wrote an interesting correspondence citing our research letter published in a previous issue of the European Respiratory Journal [1]. We compared the findings of an individual data meta-analytic observational cohort of extensively drug-resistant (XDR) tuberculosis (TB) patients [2] with those of the first experimental study on linezolid in XDR-TB subjects [3]. The results of both studies on the safety of this anti-TB drug underlined the advantage of prescribing a daily dosage of linezolid at a concentration ≤600 mg, when compared with a dosage >600 mg, once daily, in terms of a reduced proportion of adverse events [2, 3]. Interestingly, the positive tolerability response with ≤600 mg once daily of linezolid identified in both XDR-TB cohorts, had previously been confirmed in the larger, observational cohort of patients with a TB disease caused by Mycobacterium tuberculosis strains that were at least resistant to both isoniazid and rifampicin (multidrug-resistant (MDR) TB) [2]. Low linezolid dosage ≤600 mg a day for MDR-TB patients can reduce the occurrence of linezolid-related adverse events http://ow.ly/AtTVm ER -